Wegovy 1.5 mg tablets – Semaglutide Medical Information

Wegovy 1.5 mg tablets Overview

Wegovy 1.5 mg tablets is an oral tablet formulation containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It represents the starting strength in the oral Wegovy dose-escalation schedule for eligible adults receiving prescription weight-management treatment.

Semaglutide works by activating GLP-1 receptors involved in appetite regulation, food intake and blood glucose control. Its effects can help reduce hunger, increase feelings of fullness and support weight management when combined with appropriate lifestyle changes.

The 1.5 mg tablet is the initial stage of the oral treatment schedule. Subsequent strengths include 4 mg, 9 mg and 25 mg, with progression determined by the prescribing healthcare professional.

In Australia, the oral Wegovy formulation received Therapeutic Goods Administration (TGA) registration in November 2026. Registration does not necessarily mean immediate commercial availability.

Wegovy 1.5 mg Product Information

Product characteristic	Details
Brand name	Wegovy
Active ingredient	Semaglutide
Strength	1.5 mg
Dosage form	Oral tablet
Administration	Oral
Frequency	Once daily
Drug class	GLP-1 receptor agonist
Treatment stage	Initial dose
Manufacturer	Novo Nordisk
Medicine classification	Prescription-only medicine

What Is Semaglutide?

Semaglutide is a medication that mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in appetite regulation and glucose metabolism.

By activating GLP-1 receptors, semaglutide influences several physiological processes, including appetite signals, feelings of fullness, gastric emptying and glucose-dependent insulin secretion.

These effects contribute to its role in prescription treatments for weight management and certain metabolic conditions.

How Does Wegovy 1.5 mg tablets Work?

Wegovy 1.5 mg works through the activity of semaglutide on GLP-1 receptors.

The medication influences appetite-related pathways in the body, helping regulate hunger and food intake. It may also increase feelings of fullness after meals and influence the rate at which food leaves the stomach.

When used as part of an appropriate weight-management programme, semaglutide can support changes in eating habits and long-term weight management.

Individual responses vary, and treatment should be monitored by a qualified healthcare professional.

Why Is 1.5 mg the Starting Strength?

The 1.5 mg tablet is the initial strength in the oral Wegovy dose-escalation schedule.

Starting with a lower dose allows treatment to be introduced gradually. This approach helps healthcare professionals assess tolerability and manage gastrointestinal adverse reactions that may occur during treatment.

The starting strength is followed by progressively higher tablet strengths, depending on individual response and medical assessment.

The 1.5 mg tablet is not the standard maintenance strength in the published oral dosing schedule.

Wegovy Oral Tablet Dosage Schedule

The published oral semaglutide dosing schedule follows a gradual increase in tablet strength.

Treatment period	Daily strength	Treatment stage
Days 1–30	1.5 mg	Starting stage
Days 31–60	4 mg	Second stage
Days 61–90	9 mg	Third stage
Day 91 onwards	25 mg	Maintenance stage

Dose progression should be determined by the prescribing healthcare professional. Patients should not independently increase their dosage or combine multiple tablets to achieve a higher strength.

How to Take Oral Wegovy Tablets

Oral semaglutide has specific administration requirements because food, beverages and other oral medications can affect absorption.

The published administration instructions include:

• Take the tablet in the morning after an overnight fast.
• Swallow the tablet whole with plain water.
• Use no more than 120 mL of water.
• Do not crush, chew or dissolve the tablet.
• Wait at least 30 minutes before eating, drinking or taking other oral medications.

Patients should follow the Australian-approved Product Information and their prescriber’s instructions.

Possible Side Effects of Wegovy 1.5 mg tablets

Like other semaglutide-containing medicines, Wegovy may cause adverse reactions.

Commonly reported gastrointestinal effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort
• Bloating
• Indigestion
• Reduced appetite

Some adverse reactions may improve as the body adjusts to treatment. Persistent or severe symptoms should be discussed with a healthcare professional.

More serious potential risks include pancreatitis, gallbladder disease, dehydration-related kidney problems and serious allergic reactions. Severe or persistent abdominal pain requires urgent medical assessment.

Warnings and Precautions

Before starting semaglutide treatment, patients should discuss their medical history and current medications with their healthcare professional.

Important considerations include:

• Previous pancreatitis.
• Gallbladder disease or gallstones.
• Kidney problems.
• Diabetes and medications that may cause low blood glucose.
• Severe gastrointestinal conditions.
• Pregnancy or plans for pregnancy.
• Breastfeeding.
• Previous allergic reactions to semaglutide.

Semaglutide should not be used for weight reduction during pregnancy. Patients planning pregnancy should discuss treatment discontinuation with their healthcare professional.

Wegovy 1.5 mg Drug Interactions

Semaglutide may influence the absorption of certain oral medications because it can delay gastric emptying.

Patients should disclose all prescription medications, over-the-counter medicines, vitamins and supplements they use.

Additional monitoring may be necessary when semaglutide is used alongside certain diabetes medications or medicines requiring close therapeutic monitoring.

Patients should not combine different semaglutide products or other GLP-1 receptor agonists without appropriate medical direction.

Wegovy 1.5 mg tablets vs Wegovy Injection

Oral Wegovy and injectable Wegovy contain the same active ingredient, semaglutide, but have different administration methods and dosing schedules.

The oral formulation is taken once daily, while the injection is administered once weekly.

Their numerical strengths are not directly interchangeable because oral and injectable semaglutide have different absorption characteristics.

Patients should not independently switch between formulations or calculate equivalent doses.

Wegovy 1.5 mg tablets in Australia

The oral Wegovy formulation received TGA registration in Australia in November 2026.

Australian patients and healthcare professionals should consult the Australian Register of Therapeutic Goods and current product documentation for information about approved indications, prescribing requirements and supply status.

Registration should not be confused with immediate pharmacy availability or PBS subsidy.

Storage and Handling

Store Wegovy tablets according to the instructions provided in the approved product packaging and Consumer Medicine Information.

Keep medicines away from children and do not use tablets beyond their expiry date.

Consult the product documentation for specific storage conditions and handling instructions.

Frequently Asked Questions About Wegovy 1.5 mg tablets

What is Wegovy 1.5 mg tablets used for?

Wegovy 1.5 mg is the initial strength in the oral semaglutide dosing schedule. It introduces treatment gradually before potential progression to higher tablet strengths under medical supervision.

Is Wegovy 1.5 mg tablets taken daily?

Yes. The oral formulation is designed for once-daily administration, following specific fasting and water requirements.

How long is Wegovy 1.5 mg tablets taken?

The standard initial treatment period is 30 days. Subsequent dose progression depends on the prescribed schedule and individual tolerability.

What comes after Wegovy 1.5 mg tablets?

The published oral dosing schedule progresses from 1.5 mg to 4 mg, followed by 9 mg and 25 mg.

Is Wegovy 1.5 mg tablets  the same as Rybelsus?

No. Both medicines contain semaglutide, but they have different approved indications, strengths, formulations and dosing schedules. They should not be considered interchangeable.

Can Wegovy 1.5 mg tablets be taken with food?

The oral formulation should be taken after an overnight fast with plain water. Patients should wait at least 30 minutes before eating, drinking or taking other oral medicines.

Is Wegovy 1.5 mg tablets available in Australia?

The oral formulation received TGA registration in November 2026. Commercial availability should be confirmed separately with the manufacturer and Australian pharmacies.

Does Wegovy 1.5 mg tablets guarantee weight loss?

No. Individual responses vary. Semaglutide treatment should be considered as part of a comprehensive weight-management programme under medical supervision.

Medical Disclaimer

This information is provided for general educational purposes and does not replace professional medical advice, diagnosis or treatment. Wegovy is a prescription medicine. Patients should consult a qualified Australian healthcare professional before starting, changing or stopping any medication.

Medical information should be reviewed against the current Australian-approved Product Information and Consumer Medicine Information before publication.